Hostname: page-component-54dcc4c588-m259h Total loading time: 0 Render date: 2025-09-25T07:57:53.500Z Has data issue: false hasContentIssue false
  • English
  • Français

Psilocybin: Systematic review of its use in the treatment of depression

Published online by Cambridge University Press:  26 August 2025

P. Andres-Olivera ,
J. de la Iglesia ,
E. Dominguez-Alvarez ,
P. Soto’Gonzalez ,
C. P. Rodriguez ,
C. Munaiz-Cossio ,
R. K. Gonzalez-Bolaños ,
R. Brito-Rey ,
C. Marín-Lorenzo  and
B. Arribas-Simon
P. Andres-Olivera*
Affiliation:
Psichiatry, CAUSA Medicine
J. de la Iglesia
Affiliation:
Psichiatry, CAUSA Medicine
E. Dominguez-Alvarez
Affiliation:
Psichiatry, CAUSA
P. Soto’Gonzalez
Affiliation:
USAL
C. P. Rodriguez
Affiliation:
CAUSA, Salamanca
C. Munaiz-Cossio
Affiliation:
CAUSA, Salamanca
R. K. Gonzalez-Bolaños
Affiliation:
CAUSA, Salamanca
R. Brito-Rey
Affiliation:
CAUSA, Salamanca
C. Marín-Lorenzo
Affiliation:
CAUSA, Salamanca
B. Arribas-Simon
Affiliation:
Psichiatry, HCUV, Valladolid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psilocybin, a psychedelic compound, has shown potential in treating depression, especially in cases resistant to conventional treatments. This study systematically reviews the scientific literature to assess its efficacy and safety.

Objectives

The main objective of this study is to evaluate the therapeutic effects of psilocybin for the treatment of depressive disorder through a systematic review of the current scientific literature

Methods

An exhaustive search was conducted in databases such as PubMed and Web of Science, using specific MeSH term and selecting studies published between 2019-2024 that investigated the effects of psilocybin in treating depression.

Results

The included studies demonstrated significant improvements in depressive symptoms with psylocibin compared to standard treatments. Studies reports a rapid and sustained symptom reduction, with few adverse effects.

Conclusions

Psilocybin could be an effective and safe alternative for treating depression, providing symptomatic relief with fewer treatment sessions and a favorable safety profile. However, further research is needed to overcome current limitations and fully understand its therapeutic potential and underlying mechanisms.

Disclosure of Interest

None Declared

Information

Type
Abstract
Information
European Psychiatry , Volume 68 , Special Issue S1: Abstracts of the 33rd European Congress of Psychiatry , April 2025 , pp. S448
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.